Cell-based compositions and methods for treating conditions of the nervous system
AssigneeThe Johns Hopkins University
InventorsDouglas A. Kerr, Michael Gorelik, Michael Levy
Life of this patent
Estimating the term…
Abstract
Disclosed herein are cell-based compositions for the treatment of conditions of the nervous system and methods for their use. In one embodiment, a cell-based composition comprises glial-restricted progenitors (GRPs) genetically modified to express a targeting ligand on their cell surface. Methods for the preparation of such cell-based compositions are disclosed. Also disclosed is a method for treating a subject suffering from a condition of the central nervous system by providing therapeutic cells (e.g., GRPs) through an intra-arterial route of administration.
Claims23
A method for treating a demyelinating condition in a subject in need thereof, the method comprising administering to the subject a plurality of transplantation-competent GRPs, in which (i) the transplantation-competent GRPs were produced by contacting a plurality of GRPs with an agent that induces differentiation of GRPs into oligodendrocytes, and/or (ii) the administering is through an intra-arterial route.
A method for delivering GRPs to the central nervous system of a subject in need thereof, comprising administering to the subject a plurality of GRPs through an intra-arterial route.
A composition comprising a genetically modified GRP comprising an expression vector for expression of VLA-4, in which the composition is pharmaceutically acceptable for intra-arterial delivery to the central nervous system of a subject in need thereof.
A GRP comprising an exogenous VCAM-1 ligand on the cell surface or an exogenous nucleic acid encoding (a) VCAM-1 ligand or (b) a chemokine receptor.
A method for treating a CNS condition, comprising administering to a subject in need thereof a substantially pure population of therapeutic cells expressing an exogenous VCAM-1 ligand by an intra-arterial route.
A method for detecting therapeutic cells in the CNS, comprising imaging, by a non-invasive imaging technique, a region of the CNS of a subject administered the therapeutic cells by an intra-arterial route, the therapeutic cells being detectably labeled for detection by the non-invasive imaging technique and expressing an exogenous VCAM-1 ligand.
A method for treating a CNS condition, comprising dispersing a plurality of therapeutic cells to a plurality of separate brain regions in a subject in need thereof.
Dependencies are inferred from the claim text.